Back to Journals » Journal of Asthma and Allergy » Volume 13

Clinical Utility of Rush Venom Immunotherapy: Current Status

Authors Gruzelle V, Mailhol C, Waters DW, Guilleminault L

Received 19 October 2019

Accepted for publication 3 December 2019

Published 7 January 2020 Volume 2020:13 Pages 1—10

DOI https://doi.org/10.2147/JAA.S200917

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Luis Garcia-Marcos


Vianney Gruzelle,1 Claire Mailhol,2,3 David W Waters,4 Laurent Guilleminault2,4

1Department of Paediatric Pneumology and Allergology, University Hospital Centre of Toulouse, Toulouse, France; 2Department of Respiratory Medicine and Allergic Diseases, University Hospital Centre of Toulouse, Toulouse, France; 3Mastocytosis Reference Centre and Dermatology Department, University Hospital Centre of Toulouse, Toulouse, France; 4Center for Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR 5282, Toulouse III University, Toulouse, France

Correspondence: Laurent Guilleminault
Department of Respiratory Medicine and Allergic Diseases Hôpital Larrey, 24 Chemin De Pouvourville, Toulouse TSA 30030, France
Tel +335 67 77 18 50
Fax +335 67 77 14 72
Email guilleminault.l@chu-toulouse.frww

Abstract: Hymenoptera venom allergy (HVA) is the leading cause of anaphylactic reactions in adults and the second most common cause in children. Venom immunotherapy (VIT) is used to elicit an immune tolerance against hymenoptera venom in allergic patients and is based on the administration of purified venom extracts regularly for defined periods. The protocols of administration include 2 phases: an up-dosing phase that incrementally reaches the final dose resulting in a protective effect, and a maintenance phase in order to obtain the sustained effect. The goal of this review is to detail the efficacy and the safety of the up-dosing phase also named rush. Pathophysiological mechanisms, indications of VIT and technical aspects of up-dosing protocol are also covered.

Keywords: hymenoptera, allergy, immunotherapy


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]